financetom
Business
financetom
/
Business
/
Why Allbirds (BIRD) Stock Is Trading Lower
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Allbirds (BIRD) Stock Is Trading Lower
Sep 1, 2024 1:23 AM

Allbirds Inc ( BIRD ) shares are trading lower by 4.4% to 68 cents during Friday’s session after the company announced it will implement a 1-for-20 reverse stock split of its Class A and Class B Common Stock, following approval from its Board of Directors and stockholders.

The split, intended to help the company meet Nasdaq’s minimum bid price requirement, will take effect on September 4, 2024, with the stock trading on a split-adjusted basis starting September 5.

The reverse stock split will combine every 20 shares of Allbirds’ Common Stock into 1 share, with stockholders retaining the same ownership percentage post-split. No fractional shares will be issued; instead, stockholders will receive cash payments for any fractional shares.

Read Also: Fed’s Preferred Inflation Gauge Falls Short Of Expectations In July, Personal Spending Accelerates

Should I Sell My BIRD Stock?

When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.

Shares of Allbirds ( BIRD ) have decreased by 47.98% in the past year. An investor who bought shares of Allbirds ( BIRD ) at the beginning of the year would take a loss of $0.62 per share if they sold it today. The stock has risen 9.11% over the past month, meaning an investor who bought shares on Jul. 1 would see a capital gain of $0.2.

For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.

According to data from Benzinga Pro, BIRD has a 52-week high of $1.46 and a 52-week low of $0.45.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Pfizer Advances Once-Daily Weight-Loss Pill As It Catches Up To Tap The Lucrative Market
Pfizer Advances Once-Daily Weight-Loss Pill As It Catches Up To Tap The Lucrative Market
Jul 11, 2024
On Thursday, Pfizer Inc. ( PFE ) announced that, based on results from the ongoing Phase 1 pharmacokinetic study, it has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. Pfizer ( PFE ) plans to conduct dose optimization studies in the second half of 2024, evaluating multiple doses of the preferred modified...
Cornish Metals Starts Second Phase of Shaft Refurbishment at South Crofty Tin Project in U.K.
Cornish Metals Starts Second Phase of Shaft Refurbishment at South Crofty Tin Project in U.K.
Jul 11, 2024
09:42 AM EDT, 07/11/2024 (MT Newswires) -- Cornish Metals ( SBWFF ) , trading at 52 week lows, on Thursday said it has begun the second phase of shaft refurbishment at its South Crofty tin project in Cornwall, England. Vancouver-based Cornish also said it had received the initial payment for the sale of the Nickel King asset in the Northwest...
SentinelOne, Aon Collaborate to Mitigate Cyber Risk
SentinelOne, Aon Collaborate to Mitigate Cyber Risk
Jul 11, 2024
09:44 AM EDT, 07/11/2024 (MT Newswires) -- SentinelOne ( S ) and Aon (AON) are partnering to gather internal security data from SentinelOne ( S ) clients to more effectively manage and mitigate cyber risk, the companies said Thursday. SentinelOne ( S ) will provide threat detection and response technology through its Singularity Platform while Aon will assist clients using...
Biodexa Says Data Show Longevity of Effect of Potential Precancerous Polyps Treatment -- Shares Soar
Biodexa Says Data Show Longevity of Effect of Potential Precancerous Polyps Treatment -- Shares Soar
Jul 11, 2024
09:45 AM EDT, 07/11/2024 (MT Newswires) -- Biodexa Pharmaceuticals ( BDRX ) said Thursday that 12-month data from a mid-stage clinical trial showed the longevity of effect of eRapa in the treatment of precancerous polyps in the gastrointestinal tract. The company said that based on the data, eRapa showed an overall 17% median decrease in overall polyp burden and non-progression...
Copyright 2023-2026 - www.financetom.com All Rights Reserved